Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Specific genetic alterations like BRAF, RAS mutations, and fusions in NTRK, RET, ALK, and ROS1 are actionable targets in thyroid cancer.
• Oncogene addiction to these targets is effectively managed by tyrosine kinase inhibitors (TKIs).
• Acquired resistance to TKIs can emerge after initial treatment response, necessitating alternative therapeutic approaches.

Purpose of the Study:

• To review the mechanisms of acquired resistance to targeted therapies in thyroid cancer.
• To highlight the importance of molecular analysis of resistant lesions for guiding treatment decisions.
• To emphasize the need for anticipatory identification of resistance drivers and mechanisms.

Main Methods:

• Literature review of studies on targeted therapy resistance in thyroid cancer.
• Analysis of identified pathways for acquired resistance, including on-target mutations and bypass signaling.
• Discussion of the role of liquid or tissue biopsy and molecular profiling.

Main Results:

• Acquired resistance mechanisms include on-target mutations that reduce drug efficacy and activation of bypass signaling pathways.
• These resistance mechanisms can lead to tumor progression and curtail progression-free survival.
• Molecular analysis of resistant tumors is crucial for identifying new therapeutic strategies.

Conclusions:

• Acquired resistance is a significant challenge in managing thyroid cancer with targeted therapies.
• Understanding the specific mechanisms of resistance is essential for effective clinical management.
• Proactive identification and characterization of resistance drivers are necessary to overcome therapeutic limitations and improve patient survival.